{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:52:35Z","timestamp":1788051155033,"version":"build-2784847793"},"reference-count":52,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>Available evidence indicates that a therapeutic drug monitoring strategy leads to major cost savings related to the anti\u2010tumour necrosis factor\u2010\u03b1 therapy in both inflammatory bowel disease and rheumatoid arthritis (RA) patients, with no negative impact on efficacy. However, although the systematic use of therapeutic drug monitoring could potentially be beneficial and economically acceptable to drug dose optimization, it is not justifiable for all drugs. Infliximab (IFX) is a chimeric monoclonal immunoglobulin G1 targeting tumour necrosis factor. It has been approved for the treatment of immuno\u2010inflammatory diseases, including RA, ankylosing spondylitis, psoriatic arthritis, Crohn's disease and ulcerative colitis. IFX's pharmacokinetics is highly variable and influences clinical response in chronic inflammatory diseases. Clinical response increases with IFX trough concentrations in RA, ankylosing spondylitis, inflammatory bowel disease and psoriatic patients. Target concentrations predictive of good clinical response were proposed in RA, Crohn's disease and ulcerative colitis. The purpose of this article is to review the current literature surrounding IFX serum concentrations and their related parameters with disease activity in patients with spondyloarthritis. Gathering information about the efficacy of IFX in patients with spondyloarthritis and relating IFX serum concentrations to disease activity were the main goals of this study.<\/jats:p>","DOI":"10.1111\/bcp.14062","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T22:49:32Z","timestamp":1563403772000},"page":"2264-2279","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic drug monitoring of infliximab in spondyloarthritis. A review of the literature"],"prefix":"10.1111","volume":"85","author":[{"given":"Mar\u00eda Jos\u00e9","family":"Fobelo Lozano","sequence":"first","affiliation":[{"name":"Pharmacy Service Valme University Hospital  Seville Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1068-6395","authenticated-orcid":false,"given":"Reyes","family":"Serrano Gim\u00e9nez","sequence":"additional","affiliation":[{"name":"Pharmacy Service Valme University Hospital  Seville Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"S\u00e1nchez Fidalgo","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Public Health, Faculty of Medicine University of Seville  Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,8,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000289205"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175207"},{"issue":"4","key":"e_1_2_8_4_1","first-page":"241","article-title":"Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the Management of Autoimmune Diseases","volume":"29","author":"Thomas SS","year":"2015","journal-title":"A Systematic Review and Meta\u2010Analysis BioDrugs"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker124"},{"key":"e_1_2_8_6_1","unstructured":"iatdmct.org[Internet]. Rochester (NY); IATDMCT; [Cited May 22 2019]. Available from:https:\/\/www.iatdmct.org\/about\u2010us\/about\u2010association\/about\u2010definitions\u2010tdm\u2010ct.html."},{"key":"e_1_2_8_7_1","first-page":"67","article-title":"Cost\u2010effectiveness of routine measuring of serum drug concentrations and anti\u2010drug antibodies in treatment of rheumatoid arthritis patients with TNF\u2010\u03b1 blockers","volume":"10","author":"Laine J","year":"2016","journal-title":"Biol Theory"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X16676194"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-016-1266-1"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1216741"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-009-0195-8"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204172"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2017.1353602"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24275"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2016.1176635"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-014-3180-2"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203091"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318224f83d"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009740903177745"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3386"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.072397"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1032-z"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-016-3428-0"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/604872"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200828"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181cc6fef"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030452"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12142"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev356"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001043"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-015-0022-y"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13445"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000437077"},{"issue":"6","key":"e_1_2_8_35_1","first-page":"805","article-title":"Investigating the link between disease activity and infliximab serum levels in rheumatoid arthritis patients","volume":"33","author":"Valor L","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.08.035"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(73)91360-3"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.2165\/11535960-000000000-00000"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0296-9"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14410"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2014-100527"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2336-x"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22214"},{"issue":"1","key":"e_1_2_8_44_1","first-page":"145","article-title":"Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis","volume":"35","author":"Rosas J","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-018-4022-4"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04050.x"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket260"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0231-8"},{"issue":"2","key":"e_1_2_8_50_1","first-page":"228","article-title":"The prevalence and clinical effect of immunogenicity of TNF\u2010\u03b1 blockers in patients with axial spondyloarthritis","volume":"36","author":"Bornstein G","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4258"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-016-8843-5"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14062","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14062","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T19:31:32Z","timestamp":1694201492000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,6]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1111\/bcp.14062"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14062","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,6]]}}}